White House allowed agency to hire some new employees, but lawmakers remain concerned about federal hiring freeze's effect on FDA.
The US FDA apparently is reaping the benefits of an exemption to President Trump's federal hiring freeze. And while the number of new hires has yet to be revealed, it appears several new job types will be created.
Agency officials have been given the authority to fill positions that are necessary to meet mandates in the 2016 21st Century Cures Act and user fee programs, Center for
Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
